This live webinar recording explores Synthego’s cutting-edge nuclease portfolio, featuring our newest engineered nuclease, eSpOT-ON. Casey Jowdy, Senior Product Manager at Synthego, dives into its development, how its on-target and off-target profile (fidelity) compares to other Cas9 variants, and demonstrates its therapeutic potential by treating familial hypercholesterolemia. Through detailed data analysis, you will gain a deeper understanding of how eSpOT-ON enhances genome editing efficiency and how you can start using it in your work today.

This webinar also examines the key considerations for selecting the right nuclease for therapeutic applications; including licensing benefits, high-fidelity performance, and gene editing flexibility. Additionally, we present the advantages of sourcing CRISPR gRNAs and nucleases from a single provider to streamline therapeutic development, from Research Use Only (RUO) to Good Manufacturing Practice (GMP) applications demonstrated by using Synthego’s GMP SpCas9 nuclease. With its unified documentation, rigorous QC/QA validation, and high performance, you can meet regulatory requirements and accelerate your timeline to clinical success.

By the end of this session, you will have a comprehensive understanding of how Synthego’s cutting-edge nuclease portfolio is strategically designed to support CRISPR-based cell and gene therapy development, providing scientists with the best solutions for therapeutic success.